Vertex Pharmaceuticals IncorporatedVRTX
Close of Friday, October 23, 2026 · Vertex Pharmaceuticals Incorporated is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$523.95
vs its Pivot
+9.8%
OnlyAlpha Score
59
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +0.3% | +15.6% | +22.9% | +12.5% | +23.6% |
No dividend in the last 12 months.
Who runs and owns it
In these funds
Members of Congress who traded it
| Ro Khanna D · CA | 17 buys · 12 sells · last buy 2026-06-02 |
| Josh Gottheimer D · NJ | 2 buys · 4 sells · last sell 2019-09-19 |
| David Taylor R · OH | 1 buys · 2 sells · last sell 2026-08-26 |
| Gil Cisneros D · CA | 0 buys · 3 sells · last sell 2019-02-27 |
| Lisa McClain R · MI | 1 buys · 2 sells · last sell 2025-06-11 |
| Jefferson Shreve R · IN | 2 buys · 1 sells · last sell 2025-05-12 |
| Thomas MacArthur R · NJ | 2 buys · 1 sells · last buy 2016-11-02 |
| Jack Reed D · RI | 0 buys · 3 sells · last sell 2019-02-04 |
Suppliers, customers and partners
Sells to VRTX
| CRISPR Therapeutics | $205.0M upfront+milestones (diabetes license) |
| Royalty Pharma | CF franchise, $917M 2025 royalty receipts |
Partners and deals
| CRISPR Therapeutics | CASGEVY profit 60/40 |
| Moderna | CF candidate mRNA-3692/VX-522 |
From the companies' own annual reports filed with the SEC.
Healthcare · Biotech
Get VRTX in your free daily emailAfter every close: whether VRTX is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track VRTX free → Full Stock check
Track VRTX free → Full Stock check